Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Anastrozole delays bone maturation in kids with congenital adrenal hyperplasia

18 Jun 2019

The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia (CAH), reducing bone age advancement without adversely affecting bone mineral density (BMD) and visceral adipose tissue (VAT), as shown in a recent study.

Researchers looked at 25 anastrozole-treated paediatric CAH patients (mean age, 11.3 years; 56 percent boys) and 31 paediatric CAH controls not treated with the drug (mean age, 13.5 years; 29 percent boys). All participants underwent a pubertal exam, bone age X‐ray and dual X‐ray absorptiometry (DXA) scan.

Children in the anastrozole group had received the drug for an average of 5.2 years. Both the anastrozole and control groups had also been receiving chronic glucocorticoid replacement therapy and inevitably had periods of intermittent hyperandrogenaemia, as shown by the elevated bone age Z-scores.

Anastrozole produced a significant decrease in the average bone age z‐score, from 4.3 standard deviation score (SDs) at treatment initiation to 1.9 SDs at the time of DXA exam, which was conducted a mean of 5.2 years later (p=0.0004).

The anastrozole and control groups did not significantly differ in terms of total BMD z‐scores (p=0.51), L2‐L4 BMD z‐scores (p=0.66), VAT (p=0.38), total BMD adjusted for height-for-age z-scores (TMBDHAZ; p=0.66) and L2‐L4HAZ z-scores (p=0.41).

According to the researchers, the similarity in BMD observed between children receiving vs not receiving anastrozole indicates that “the direct effect of potentially higher androgen levels from blocking aromatization in children treated with anastrozole may compensate for the effect of decreased oestrogen levels on bone and may offset some of the negative effects of glucocorticoids.”

The described effect could also explain the absence of difference in VAT between the two patient groups, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 10 Jul 2019

Women who receive a single dose of amoxicillin and clavulanic acid within 6 hours of operative vaginal delivery could significantly reduce their postpartum infection risk, according to the UK-based ANODE* trial.

17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
Audrey Abella, 05 Jul 2018
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.